Abstract
Locus coeruleus (LC) neurons in the brainstem send extensive noradrenergic (NE)-ergic terminals to the majority of brain regions, particularly those involved in cognitive function. Both Alzheimer’s disease (AD) and Down syndrome (DS) are characterized by similar pathology including significant LC degeneration and dysfunction of the NE-ergic system. Extensive loss of NE-ergic terminals has been linked to alterations in brain regions vital for cognition, mood, and executive function. While the mechanisms by which NE-ergic abnormalities contribute to cognitive dysfunction are not fully understood, emergent evidence suggests that rescue of NE-ergic system can attenuate neuropathology and cognitive decline in both AD and DS. Therapeutic strategies to enhance NE neurotransmission have undergone limited testing. Among those deployed to date are NE reuptake inhibitors, presynaptic α-adrenergic receptor antagonists, NE prodrugs, and β-adrenergic agonists. Here we examine alterations in the NE-ergic system in AD and DS and suggest that NE-ergic system rescue is a plausible treatment strategy for targeting cognitive decline in both disorders.
Keywords: Adrenergic system, Alzheimer’s disease, β-Adrenergic, Monoaminergic systems, Down syndrome, Dementia, Locus coeruleus.
Current Alzheimer Research
Title:Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Volume: 13 Issue: 1
Author(s): Cristy Phillips, Atoossa Fahimi, Devsmita Das, Fatemeh S. Mojabi, Ravikumar Ponnusamy and Ahmad Salehi
Affiliation:
Keywords: Adrenergic system, Alzheimer’s disease, β-Adrenergic, Monoaminergic systems, Down syndrome, Dementia, Locus coeruleus.
Abstract: Locus coeruleus (LC) neurons in the brainstem send extensive noradrenergic (NE)-ergic terminals to the majority of brain regions, particularly those involved in cognitive function. Both Alzheimer’s disease (AD) and Down syndrome (DS) are characterized by similar pathology including significant LC degeneration and dysfunction of the NE-ergic system. Extensive loss of NE-ergic terminals has been linked to alterations in brain regions vital for cognition, mood, and executive function. While the mechanisms by which NE-ergic abnormalities contribute to cognitive dysfunction are not fully understood, emergent evidence suggests that rescue of NE-ergic system can attenuate neuropathology and cognitive decline in both AD and DS. Therapeutic strategies to enhance NE neurotransmission have undergone limited testing. Among those deployed to date are NE reuptake inhibitors, presynaptic α-adrenergic receptor antagonists, NE prodrugs, and β-adrenergic agonists. Here we examine alterations in the NE-ergic system in AD and DS and suggest that NE-ergic system rescue is a plausible treatment strategy for targeting cognitive decline in both disorders.
Export Options
About this article
Cite this article as:
Phillips Cristy, Fahimi Atoossa, Das Devsmita, Mojabi S. Fatemeh, Ponnusamy Ravikumar and Salehi Ahmad, Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy, Current Alzheimer Research 2016; 13 (1) . https://dx.doi.org/10.2174/1567205012666150921095924
DOI https://dx.doi.org/10.2174/1567205012666150921095924 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Pivotal Role of Nitric Oxide: Effects on the Nervous and Immune Systems
Current Pharmaceutical Design Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Quinazolin-4-One: A Varsatile Molecule
Current Bioactive Compounds Diabetes Mellitus: Novel Insights, Analysis and Interpretation of Pathophysiology and Complications Management with Imidazole-Containing Peptidomimetic Antioxidants
Recent Patents on Drug Delivery & Formulation Ruta Montana Evokes Antihypertensive Activity Through an Increase of Prostaglandins Release in L-NAME-Induced Hypertensive Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Biological Toxins and Medicinal Chemistry: Research and Therapeutic Tools)
Current Topics in Medicinal Chemistry Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Toxicological Effects of Dietary Biogenic Amines
Current Nutrition & Food Science Anti-Ophidian Properties of Herbal Medicinal Plants: Could it be a Remedy for Snake Bite Envenomation?
Current Drug Discovery Technologies Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy Triterpenes from Gloeophyllum odoratum as Potential Leads Towards Potent Thrombin Inhibitors
Letters in Drug Design & Discovery Recent Patents in the Field of Radioprotector Development: Opportunities and Challenges
Recent Patents on Biotechnology Safe and Effective Delivery of Amphotericin B: A Survey of Patents
Recent Patents on Nanotechnology Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews Targeting <i>Plasmodium Metabolism</i> to Improve Antimalarial Drug Design
Current Protein & Peptide Science Enkephalinase Inhibitors: Potential Agents for the Management of Pain
Current Drug Targets Late Life Depression: A Diagnostic and Pharmacological Review
Current Psychopharmacology A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure
Current Cardiology Reviews